-
EP2648747
European procedure
Extract from the Register of European Patents
EP About this file: EP2648747
| EP2648747 - ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND BORTEZOMIB [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 14.06.2019 Database last updated on 03.09.2024 | |
| Former | The patent has been granted Status updated on 06.07.2018 | ||
| Former | Grant of patent is intended Status updated on 27.02.2018 | ||
| Former | Examination is in progress Status updated on 03.01.2017 | Most recent event Tooltip | 26.06.2020 | Lapse of the patent in a contracting state New state(s): MK | published on 29.07.2020 [2020/31] | Applicant(s) | For all designated states SANOFI 54, rue La Boétie 75008 Paris / FR | [2017/34] |
| Former [2013/42] | For all designated states Sanofi 174 avenue de France 75013 Paris / FR | Inventor(s) | 01 /
DECKERT, Jutta 830 Winter Street Waltham, MA 02451 / US | 02 /
LEJEUNE, Pascale c/o Sanofi Patent Department 174 Avenue de France 75013 Paris / FR | 03 /
MAYO, Michele F 830 Winter Street Waltham, MA 02451 / US | 04 /
PARK, Peter U 830 Winter Street Waltham, MA 02451 / US | [2018/32] |
| Former [2013/42] | 01 /
DECKERT, Jutta 830 Winter Street Waltham, Massachusetts 02451 / US | ||
| 02 /
LEJEUNE, Pascale c/o Sanofi Patent Department 174 Avenue de France F-75013 Paris / FR | |||
| 03 /
MAYO, Michele F 830 Winter Street Waltham, Massachusetts 02451 / US | |||
| 04 /
PARK, Peter U 830 Winter Street Waltham, Massachusetts 02451 / US | Representative(s) | Lavoix 2, place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | [2018/32] |
| Former [2013/42] | Jacobson, Claude, et al Cabinet Lavoix 2, Place d'Estienne d'Orves 75441 Paris Cedex 09 / FR | Application number, filing date | 11801669.0 | 08.12.2011 | [2018/32] | WO2011EP72228 | Priority number, date | EP20100306395 | 10.12.2010 Original published format: EP 10306395 | [2013/42] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012076663 | Date: | 14.06.2012 | Language: | EN | [2012/24] | Type: | A1 Application with search report | No.: | EP2648747 | Date: | 16.10.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.06.2012 takes the place of the publication of the European patent application. | [2013/42] | Type: | B1 Patent specification | No.: | EP2648747 | Date: | 08.08.2018 | Language: | EN | [2018/32] | Search report(s) | International search report - published on: | EP | 14.06.2012 | Classification | IPC: | A61K39/395, A61K45/06, C07K16/28, A61P35/00 | [2013/42] | CPC: |
A61K39/39558 (EP,CN,IL,US);
A61K39/00 (IL);
A61K39/395 (KR);
A61K31/69 (CN,IL);
A61K38/05 (EP,CN,IL,US);
A61K39/3955 (EP,IL,US);
A61K45/06 (KR);
A61P35/00 (EP);
A61P35/02 (EP);
A61P43/00 (EP);
C07K16/28 (CN,IL,KR);
C07K16/2896 (EP,IL,US);
A61K2039/542 (CN,IL);
A61K2039/545 (CN,IL);
C07K2317/24 (EP,CN,IL,US);
C07K2317/51 (CN,IL);
C07K2317/515 (CN,IL);
C07K2317/565 (CN,IL);
| C-Set: |
A61K31/69, A61K2300/00 (CN);
A61K38/05, A61K2300/00 (EP,CN,US);
A61K39/39558, A61K2300/00 (US,CN,EP);
A61K39/3955, A61K2300/00 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/42] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | ANTITUMORKOMBINATIONEN VON ANTIKÖRPERN, DIE SPEZIFISCH CD38 ERKENNEN MIT BORTEZOMIB | [2018/09] | English: | ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND BORTEZOMIB | [2013/42] | French: | COMBINAISONS ANTITUMORALES CONTENANT DES ANTICORPS RECONNAISSANT SPÉCIFIQUEMENT LES CD38 ET BORTÉZOMIB | [2018/09] |
| Former [2013/42] | ANTITUMORKOMBINATIONEN MIT ANTIKÖRPERN MIT GEZIELTER ERKENNUNG VON CD38 UND BORTEZOMIB | ||
| Former [2013/42] | COMBINAISONS ANTITUMORALES CONTENANT DES ANTICORPS RECONNAISSANT SPÉCIFIQUEMENT LE CD38 ET DU BORTÉZOMIB | Entry into regional phase | 10.07.2013 | National basic fee paid | 10.07.2013 | Designation fee(s) paid | 10.07.2013 | Examination fee paid | Examination procedure | 10.07.2013 | Examination requested [2013/42] | 07.01.2014 | Amendment by applicant (claims and/or description) | 21.03.2014 | Despatch of communication of loss of particular rights: Claims {1} | 23.10.2015 | Despatch of a communication from the examining division (Time limit: M06) | 14.04.2016 | Reply to a communication from the examining division | 08.09.2016 | Despatch of a communication from the examining division (Time limit: M04) | 22.12.2016 | Reply to a communication from the examining division | 04.01.2018 | Cancellation of oral proceeding that was planned for 12.01.2018 | 12.01.2018 | Date of oral proceedings (cancelled) | 28.02.2018 | Communication of intention to grant the patent | 28.06.2018 | Fee for grant paid | 28.06.2018 | Fee for publishing/printing paid | 28.06.2018 | Receipt of the translation of the claim(s) | Divisional application(s) | EP18180404.8 / EP3412311 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 23.10.2015 | Opposition(s) | 09.05.2019 | No opposition filed within time limit [2019/29] | Request for further processing for: | Loss of rights: Claims | 16.05.2014 | Request for further processing filed | 16.05.2014 | Full payment received (date of receipt of payment) Request granted | 26.05.2014 | Decision despatched | Fees paid | Renewal fee | 12.12.2013 | Renewal fee patent year 03 | 11.12.2014 | Renewal fee patent year 04 | 10.12.2015 | Renewal fee patent year 05 | 13.12.2016 | Renewal fee patent year 06 | 12.12.2017 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 08.08.2018 | MK | 08.08.2018 | SM | 08.08.2018 | IS | 08.12.2018 | [2020/31] |
| Former [2019/26] | AL | 08.08.2018 | |
| SM | 08.08.2018 | ||
| IS | 08.12.2018 | ||
| Former [2019/13] | AL | 08.08.2018 | |
| IS | 08.12.2018 | ||
| Former [2019/08] | IS | 08.12.2018 | Cited in | International search | [YD]WO2008047242 (SANOFI AVENTIS [FR], et al) [YD] 1-16 * claims 1,63, 65; sequences 62, 64, 66, 68, 70, 72 *; | [Y]WO2010061357 (SANOFI AVENTIS [FR], et al) [Y] 1-16 * pages 1,9; claims 1,3-6; sequences 1-36,62, 64, 66, 68, 70, 72 *; | [Y]WO2010061358 (SANOFI AVENTIS [FR], et al) [Y] 1-16 * pages 1,9; claims 1, 3-6; sequences 1-36, 62, 64, 66, 68, 70, 72 *; | [Y]WO2010061359 (SANOFI AVENTIS [FR], et al) [Y] 1-16 * pages 1,9; claims 1, 3-6,; sequences 1-36, 62, 64, 66, 68, 70, 72 *; | [Y]WO2010061360 (SANOFI AVENTIS [FR], et al) [Y] 1-16 * pages 1,9; claims 1, 3-6; sequences 1-36,62, 64, 66, 68, 70, 72 *; | [Y] - WALSBY ELISABETH J ET AL, "The NF-KB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib", MOLECULAR CANCER THERAPEUTICS, (201006), vol. 9, no. 6, ISSN 1535-7163, pages 1574 - 1582, XP002646652 [Y] 1-16 * page 1574, column 2, paragraph 1 * DOI: http://dx.doi.org/10.1158/1535-7163.mct-10-0104 | by applicant | US4444887 | EP0239400 | US4716111 | WO9109967 | WO9110741 | WO9222653 | EP0519596 | EP0592106 | US5530101 | US5545806 | US5565332 | WO9634096 | WO9633735 | US5585089 | US5639641 | WO9816654 | WO9824893 | US5814318 | WO9846645 | WO9850433 | US2008074381 | WO2008047242 | - PADLAN E. A., MOLECULAR IMMUNOLOGY, (1991), vol. 28, no. 4-5, pages 489 - 498 | - STUDNICKA G. M. ET AL., PROTEIN ENGINEERING, (1994), vol. 7, no. 6, pages 805 - 814 | - ROGUSKA M.A. ET AL., PNAS, (1994), vol. 91, pages 969 - 973 | - RICHARDSON ET AL., N. ENGL. J. MED., (2005), vol. 352, pages 2487 - 2498 | - BOCCADORO ET AL., CANCER CELL INT., (2005), vol. 5, no. 1, page 18 | - T.H. CORBETT ET AL., CANCER, (1977), vol. 40, pages 2660 - 2680 | - F.M. SCHABEL ET AL., Cancer Drug Development, Part B, Methods in Cancer Research, ACADEMIC PRESS INC., (1979), vol. 17, pages 3 - 51 |